Crossmark

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Crossref DOI link: https://doi.org/10.1038/nature19771

Published Online: 2016-09-28

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Jimi

McMillan, Elizabeth

Kim, Hyun Seok

Venkateswaran, Niranjan

Makkar, Gurbani

Rodriguez-Canales, Jaime

Villalobos, Pamela

Neggers, Jasper Edgar

Mendiratta, Saurabh

Wei, Shuguang

Landesman, Yosef

Senapedis, William

Baloglu, Erkan

Chow, Chi-Wan B.

Frink, Robin E.

Gao, Boning

Roth, Michael

Minna, John D.

Daelemans, Dirk

Wistuba, Ignacio I.

Posner, Bruce A.

Scaglioni, Pier Paolo

White, Michael A.
License Information

Text and Data Mining valid from 2016-09-28
More Information

Article History

Received: 20 August 2015

Accepted: 17 August 2016

First Online: 28 September 2016

Change Date: 5 October 2016

Change Type: Correction

Change Details: The address details for Karyopharm Therapeutics were corrected.

Competing interests

: The authors declare no competing financial interests.